2016
Stroke Treatment Academic Industry Roundtable Recommendations for Individual Data Pooling Analyses in Stroke
Lees K, Khatri P, Alexandrov A, Bivard A, Boltze J, Broderick J, Campbell B, Creighton F, Fiorella D, Furlan A, Gorelick P, Hess D, Kim W, Latour L, Liebeskind D, Luby M, Lyden P, Lynch J, Marshall R, Menon B, Muir K, Palesch Y, Peng H, Pryor K, Mocco J, Rasmussen P, Sacco R, Schwamm L, Smith E, Solberg Y, Vagal A, Warach S, Wechsler L, Wintermark M, Yoo A, Zander K. Stroke Treatment Academic Industry Roundtable Recommendations for Individual Data Pooling Analyses in Stroke. Stroke 2016, 47: 2154-2159. PMID: 27406108, PMCID: PMC4961517, DOI: 10.1161/strokeaha.116.012966.Peer-Reviewed Original ResearchMeSH KeywordsClinical Trials as TopicHumansMeta-Analysis as TopicResearch DesignStatistics as TopicStrokeConceptsPooled analysisClinical implicationsClinical trial findingsIndividual patient dataPooled findingsPrespecified subgroupsOngoing trialsStroke trialsTrial findingsTreatment strategiesClinical careIndividual drugsPooling analysisTrial teamSuch drugsClass effectSevere disabilityTrial resultsPatient dataAnalysis planTrialsStatistical adjustmentTreatment effectsAcute Stroke Imaging Research Roadmap III Imaging Selection and Outcomes in Acute Stroke Reperfusion Clinical Trials
Warach S, Luby M, Albers G, Bammer R, Bivard A, Campbell B, Derdeyn C, Heit J, Khatri P, Lansberg M, Liebeskind D, Majoie C, Marks M, Menon B, Muir K, Parsons M, Vagal A, Yoo A, Alexandrov A, Baron J, Fiorella D, Furlan A, Puig J, Schellinger P, Wintermark M, Ansari S, Aviv R, Barreto A, Broderick J, Christensen S, Davis S, Demchuk A, Dippel D, Donnan G, Fiebach J, Fiehler J, Houser G, Grotta J, Hacke W, Hill M, Hsia A, Jovin T, Köhrmann M, Latour L, Leigh R, Lees K, Lev M, Marshall R, Mocco J, Nadareishvili Z, Nogueira R, Olivot J, Palesch Y, Pedraza S, Sasaki M, Saver J, Savitz S, Schwamm L, Simpkins A, Smith W, Thijs V, Thomalla G, Wechsler L, Wu O, Zaharchuk G, Zaidat O. Acute Stroke Imaging Research Roadmap III Imaging Selection and Outcomes in Acute Stroke Reperfusion Clinical Trials. Stroke 2016, 47: 1389-1398. PMID: 27073243, PMCID: PMC6058693, DOI: 10.1161/strokeaha.115.012364.Peer-Reviewed Original ResearchMeSH KeywordsClinical Trials as TopicConsensusEducationEndovascular ProceduresHumansNeuroimagingStrokeThrombolytic TherapyConceptsClinical trialsEndovascular trialsImaging Working GroupFinal infarct volumeLarge vessel occlusionProspective clinical trialsImaging sessionAmerican SocietyOptimal imaging methodInfarct volumeStroke neurologistsEndovascular treatmentPooled analysisTherapy clinical trialsVessel occlusionImaging selectionGood collateralsNeurovascular imagingConsensus recommendationsUS FoodDrug AdministrationNeurological disordersPooled dataTrialsNational Institute
2014
Adherence to Third European Cooperative Acute Stroke Study 3- to 4.5-Hour Exclusions and Association With Outcome
Cronin CA, Sheth KN, Zhao X, Messé SR, Olson DM, Hernandez AF, Bhatt DL, Schwamm LH, Smith EE. Adherence to Third European Cooperative Acute Stroke Study 3- to 4.5-Hour Exclusions and Association With Outcome. Stroke 2014, 45: 2745-2749. PMID: 25104846, DOI: 10.1161/strokeaha.114.005443.Peer-Reviewed Original ResearchConceptsAdditional exclusion criteriaExclusion criteriaDiabetes mellitusAmerican Heart Association/American Stroke Association guidelinesEuropean Cooperative Acute Stroke StudyAmerican Stroke Association guidelinesSymptomatic intracranial hemorrhageWorse hospital outcomesHealth Stroke ScalePercent of patientsHistory of strokeOral anticoagulant treatmentCertain patient groupsAcute Stroke StudyTreatment time windowHour windowECASS IIIGuidelines-StrokePrior strokeAnticoagulant treatmentHospital outcomesStroke ScaleIschemic strokeSymptom onsetIncreased risk
2013
Factors Influencing the Decline in Stroke Mortality
Lackland DT, Roccella EJ, Deutsch AF, Fornage M, George MG, Howard G, Kissela BM, Kittner SJ, Lichtman JH, Lisabeth LD, Schwamm LH, Smith EE, Towfighi A. Factors Influencing the Decline in Stroke Mortality. Stroke 2013, 45: 315-353. PMID: 24309587, PMCID: PMC5995123, DOI: 10.1161/01.str.0000437068.30550.cf.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge FactorsAgedAged, 80 and overAir PollutionAmerican Heart AssociationAspirinAssociationAtrial FibrillationBlood PressureClinical Trials as TopicDiabetes MellitusExerciseFemaleHeart DiseasesHumansHyperlipidemiasHypertensionIncidenceInternational Classification of DiseasesMaleMiddle AgedObesityObservational Studies as TopicPlatelet Aggregation InhibitorsPopulationPrevalenceSecondary PreventionSex FactorsSmokingStrokeThrombolytic TherapyUnited StatesYoung AdultConceptsStroke mortalityCause of deathStroke riskAmerican Heart Association Stroke Council's Scientific Statement Oversight CommitteeAmerican Heart Association's Manuscript Oversight CommitteeAmerican Heart Association Science AdvisoryScientific Statements Oversight Committee reviewStroke Council Leadership reviewLower case fatality rateEvidence-based public health programsMajor public health burdenControl of hypertensionChronic lung diseaseFourth leading causeCase fatality rateTreatment of hypertensionPublic health burdenWriting group membersAttributable risk estimatesPublic health guidelinesYears of ageMajor public healthPublic health programsCombination of interventionsDyslipidemia control
2011
Use of Telemedicine and Other Strategies to Increase the Number of Patients That May Be Treated with Intravenous Thrombolysis
Silva G, Schwamm L. Use of Telemedicine and Other Strategies to Increase the Number of Patients That May Be Treated with Intravenous Thrombolysis. Current Neurology And Neuroscience Reports 2011, 12: 10-16. PMID: 21997715, DOI: 10.1007/s11910-011-0235-6.Peer-Reviewed Original ResearchMeSH KeywordsClinical Trials as TopicFibrinolytic AgentsHumansInfusions, IntravenousStrokeTelemedicineThrombolytic TherapyTime FactorsTissue Plasminogen ActivatorUnited StatesConceptsAcute ischemic strokeUse of telemedicineIntravenous thrombolysisIschemic strokeIntravenous tissue plasminogen activator useAdult long-term disabilityTissue plasminogen activator useLong-term disabilityAmerican Heart AssociationNumber of patientsRecruitment of patientsRate of treatmentHelp of telemedicineThrombolysis trialsHeart AssociationStroke NetworkStroke systemsTelestroke networkTelestroke systemCurrent evidencePatientsThrombolysisStrokeCareTelemedicine
2010
Rapid Change in Prescribing Behavior in Hospitals Participating in Get With The Guidelines–Stroke After Release of the Management of Atherothrombosis With Clopidogrel in High-Risk Patients (MATCH) Clinical Trial Results
Menon B, Frankel M, Liang L, LaBresh K, Ellrodt G, Hernandez A, Fonarow G, Schwamm L, Smith E. Rapid Change in Prescribing Behavior in Hospitals Participating in Get With The Guidelines–Stroke After Release of the Management of Atherothrombosis With Clopidogrel in High-Risk Patients (MATCH) Clinical Trial Results. Stroke 2010, 41: 2094-2097. PMID: 20634476, DOI: 10.1161/strokeaha.110.584151.Peer-Reviewed Original ResearchConceptsTransient ischemic attackIschemic attackIschemic strokeHigh-risk patients trialAmerican Heart Association Guidelines UpdateManagement of AtherothrombosisPatient clinical trialsGuidelines-StrokeGWTG-StrokeAntithrombotic medicationAntithrombotic therapyStroke ProgramDischarge prescriptionsGuideline updateRandomized trialsConsensus guidelinesHospital characteristicsClinical trialsPrescribing behaviorSustained decreasePatient trialsSustained reductionClinical informationPatientsMatch Study
2009
Number Needed to Treat to Benefit and to Harm for Intravenous Tissue Plasminogen Activator Therapy in the 3- to 4.5-Hour Window
Saver J, Gornbein J, Grotta J, Liebeskind D, Lutsep H, Schwamm L, Scott P, Starkman S. Number Needed to Treat to Benefit and to Harm for Intravenous Tissue Plasminogen Activator Therapy in the 3- to 4.5-Hour Window. Stroke 2009, 40: 2433-2437. PMID: 19498197, PMCID: PMC2724988, DOI: 10.1161/strokeaha.108.543561.Peer-Reviewed Original ResearchMeSH KeywordsAlgorithmsClinical Trials as TopicFibrinolytic AgentsHumansStrokeThrombolytic TherapyTime FactorsTissue Plasminogen ActivatorTreatment OutcomeConceptsTissue plasminogen activatorRankin ScaleIntravenous tissue plasminogen activator therapyIntravenous tissue plasminogen activatorTissue plasminogen activator therapyPlasminogen activatorAcute cerebral ischemiaModified Rankin ScalePlasminogen activator therapyResults of therapyEffect sizeCerebral ischemiaPoststroke disabilityAdditional patientsActivator therapyWorse outcomesGlobal disabilityTreatment decisionsBetter outcomesClinical practicePatientsNNTBLikelihood of helpEffect size estimatesTable analysis
2008
Quantitative Assessment of Core/Penumbra Mismatch in Acute Stroke
Schaefer P, Barak E, Kamalian S, Gharai L, Schwamm L, Gonzalez R, Lev M. Quantitative Assessment of Core/Penumbra Mismatch in Acute Stroke. Stroke 2008, 39: 2986-2992. PMID: 18723425, DOI: 10.1161/strokeaha.107.513358.Peer-Reviewed Original ResearchConceptsCT perfusionPatient selectionInfarct coreAcute middle cerebral artery strokeMiddle cerebral artery strokePreferred imaging methodStroke clinical trialsAcute strokeArtery strokeStroke trialsTrial enrollmentClinical trialsLesion volumeMR perfusionIschemic regionBlood volumeTime abnormalitiesVolume thresholdLesion sizeQuantitative CTPerfusionAdvanced MRCT coverageLesionsMR diffusionUpdate to the AHA/ASA Recommendations for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
Adams R, Albers G, Alberts M, Benavente O, Furie K, Goldstein L, Gorelick P, Halperin J, Harbaugh R, Johnston S, Katzan I, Kelly-Hayes M, Kenton E, Marks M, Sacco R, Schwamm L. Update to the AHA/ASA Recommendations for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack. Stroke 2008, 39: 1647-1652. PMID: 18322260, PMCID: PMC4198335, DOI: 10.1161/strokeaha.107.189063.Peer-Reviewed Original Research
2006
Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack
Sacco R, Adams R, Albers G, Alberts M, Benavente O, Furie K, Goldstein L, Gorelick P, Halperin J, Harbaugh R, Johnston S, Katzan I, Kelly-Hayes M, Kenton E, Marks M, Schwamm L, Tomsick T. Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack. Stroke 2006, 37: 577-617. PMID: 16432246, DOI: 10.1161/01.str.0000199147.30016.74.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAlcohol DrinkingAnti-Inflammatory Agents, Non-SteroidalBlood PressureBrain IschemiaClinical Trials as TopicComorbidityCoronary DiseaseDiabetes ComplicationsFemaleHumansHypertensionIschemic Attack, TransientMaleMiddle AgedObesityPrevalenceRiskRisk AssessmentRisk FactorsRisk Reduction BehaviorSmokingStrokeUnited StatesConceptsTransient ischemic attackEvidence-based recommendationsIschemic strokeIschemic attackCerebral venous sinus thrombosisTimely evidence-based recommendationsUse of anticoagulationVenous sinus thrombosisPrevention of strokeHigh-risk populationSickle cell diseaseImplementation of guidelinesAntithrombotic treatmentRecurrent strokeSinus thrombosisNoncardioembolic strokePostmenopausal hormonesAntiplatelet agentsArterial dissectionHypercoagulable statePatent foramenAtherosclerotic diseaseCerebral hemorrhageRisk factorsInterventional approaches